vigabatrin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
gabamimetic agents	2819	68506-86-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vigabatrin (+/-)-4-Amino-5-hexenoic acid sabril vigabatrin hydrochloride vigabatrin HCl	The precise mechanism of vigabatrin's anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system. Molecular weight: 129.16 Formula: C6H11NO2 CLOGP: -2.22 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 63.32 ALOGS: -0.13 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vigabatrin
(+/-)-4-Amino-5-hexenoic acid
sabril
vigabatrin hydrochloride
vigabatrin HCl

The precise mechanism of vigabatrin's anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system.

Molecular weight: 129.16
Formula: C6H11NO2
CLOGP: -2.22
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 63.32
ALOGS: -0.13
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	60 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	442.42 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Aug. 21, 2009	FDA	LUNDBECK LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1749.00	32.41	613	6050	132021	63350338
Drug withdrawal convulsions	670.35	32.41	118	6545	1307	63481052
Product dose omission issue	282.93	32.41	217	6446	234096	63248263
Retinogram abnormal	276.24	32.41	41	6622	130	63482229
Magnetic resonance imaging head abnormal	273.77	32.41	59	6604	1954	63480405
Status epilepticus	270.91	32.41	89	6574	15144	63467215
Death	233.01	32.41	238	6425	374143	63108216
Drug ineffective	214.07	32.41	385	6278	1044380	62437979
Irritability	159.27	32.41	74	6589	31620	63450739
Drug resistance	158.59	32.41	67	6596	22866	63459493
Somnolence	147.29	32.41	133	6530	178552	63303807
Multiple-drug resistance	132.67	32.41	40	6623	5130	63477229
Visual field defect	131.47	32.41	42	6621	6519	63475840
Infantile spasms	122.61	32.41	21	6642	194	63482165
Epilepsy	114.01	32.41	56	6607	27009	63455350
Brain operation	100.79	32.41	21	6642	588	63481771
Aggression	91.21	32.41	46	6617	23452	63458907
Generalised tonic-clonic seizure	76.68	32.41	44	6619	28972	63453387
Tonic convulsion	75.00	32.41	19	6644	1278	63481081
Focal dyscognitive seizures	72.36	32.41	22	6641	2899	63479460
Optic atrophy	70.35	32.41	18	6645	1260	63481099
Intellectual disability	68.22	32.41	17	6646	1069	63481290
Change in seizure presentation	66.61	32.41	14	6649	409	63481950
Respiratory distress	65.29	32.41	42	6621	33909	63448450
Partial seizures	64.67	32.41	24	6639	5818	63476541
Abnormal behaviour	63.41	32.41	35	6628	21391	63460968
Bronchiolitis	56.73	32.41	18	6645	2729	63479630
Retinal injury	49.71	32.41	10	6653	234	63482125
Seizure cluster	49.55	32.41	10	6653	238	63482121
Pneumonia	48.14	32.41	130	6533	456637	63025722
Respiratory failure	47.58	32.41	56	6607	101802	63380557
Coma blister	47.58	32.41	9	6654	151	63482208
Hypotonia	47.58	32.41	22	6641	9263	63473096
Pain	47.57	32.41	10	6653	740618	62741741
Infantile spitting up	45.95	32.41	8	6655	82	63482277
Pneumonia aspiration	45.81	32.41	34	6629	34506	63447853
Temporal lobe epilepsy	44.51	32.41	10	6653	401	63481958
Epidural lipomatosis	43.72	32.41	8	6655	111	63482248
Retinal disorder	43.02	32.41	13	6650	1677	63480682
Ophthalmological examination abnormal	40.27	32.41	7	6656	71	63482288
Nausea	38.55	32.41	21	6642	854450	62627909
Crying	37.91	32.41	26	6637	23317	63459042
Anticonvulsant drug level decreased	37.84	32.41	11	6652	1241	63481118
Neurotoxicity	37.63	32.41	23	6640	16967	63465392
Rhinovirus infection	37.27	32.41	15	6648	4514	63477845
Visual impairment	35.46	32.41	44	6619	84402	63397957
Respiratory syncytial virus bronchiolitis	35.46	32.41	8	6655	327	63482032
Blindness	34.84	32.41	24	6639	21675	63460684
Respiratory syncytial virus infection	34.01	32.41	16	6647	7002	63475357
Hypoventilation	33.19	32.41	14	6649	4740	63477619

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1614.09	39.36	637	6063	104220	34846011
Drug withdrawal convulsions	590.64	39.36	113	6587	1064	34949167
Product dose omission issue	335.72	39.36	234	6466	119477	34830754
Drug ineffective	262.94	39.36	374	6326	456377	34493854
Magnetic resonance imaging head abnormal	245.17	39.36	56	6644	1305	34948926
Status epilepticus	242.16	39.36	91	6609	12523	34937708
Visual field defect	213.04	39.36	64	6636	4419	34945812
Retinogram abnormal	210.77	39.36	34	6666	99	34950132
Death	122.90	39.36	248	6452	397801	34552430
Multiple-drug resistance	115.94	39.36	42	6658	5197	34945034
Infantile spasms	110.47	39.36	21	6679	189	34950042
Brain operation	106.18	39.36	22	6678	318	34949913
Epilepsy	105.07	39.36	60	6640	21435	34928796
Infantile spitting up	100.38	39.36	16	6684	42	34950189
Somnolence	97.51	39.36	113	6587	111003	34839228
Partial seizures	86.40	39.36	33	6667	4727	34945504
Anticonvulsant drug level above therapeutic	85.83	39.36	21	6679	661	34949570
Visual impairment	81.56	39.36	62	6638	35740	34914491
Excessive eye blinking	79.52	39.36	19	6681	540	34949691
Sudden unexplained death in epilepsy	77.17	39.36	18	6682	460	34949771
Adverse event	74.72	39.36	46	6654	18831	34931400
Gaze palsy	70.88	39.36	22	6678	1690	34948541
Ophthalmological examination abnormal	68.70	39.36	11	6689	30	34950201
Irritability	68.08	39.36	48	6652	24642	34925589
Optic atrophy	65.58	39.36	18	6682	896	34949335
Aggression	58.49	39.36	53	6647	38911	34911320
Generalised tonic-clonic seizure	55.68	39.36	40	6660	21134	34929097
Respiratory syncytial virus infection	55.68	39.36	24	6676	4685	34945546
Eye movement disorder	55.34	39.36	23	6677	4104	34946127
Respiratory distress	52.52	39.36	48	6652	35617	34914614
Tonic convulsion	52.11	39.36	16	6684	1185	34949046
Crying	50.64	39.36	24	6676	5838	34944393
Posture abnormal	49.71	39.36	18	6682	2221	34948010
Postictal paralysis	48.26	39.36	11	6689	253	34949978
Abnormal behaviour	47.69	39.36	39	6661	24930	34925301
Acute kidney injury	46.78	39.36	3	6697	304985	34645246
Hospitalisation	45.04	39.36	55	6645	56847	34893384
Myoclonic epilepsy	44.27	39.36	14	6686	1143	34949088
Cerebral disorder	43.52	39.36	17	6683	2584	34947647
Seizure cluster	42.93	39.36	9	6691	138	34950093
Retinal disorder	42.32	39.36	13	6687	964	34949267
Hypotonia	41.25	39.36	23	6677	7830	34942401
Pneumonia	41.02	39.36	157	6543	362470	34587761
Respiratory disorder	40.86	39.36	32	6668	19232	34930999

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1902.79	31.52	741	8711	188093	79546843
Drug withdrawal convulsions	777.92	31.52	146	9306	2074	79732862
Retinogram abnormal	457.31	31.52	71	9381	282	79734654
Product dose omission issue	456.81	31.52	311	9141	247226	79487710
Status epilepticus	442.53	31.52	150	9302	24891	79710045
Death	349.30	31.52	379	9073	566135	79168801
Magnetic resonance imaging head abnormal	259.20	31.52	61	9391	2665	79732271
Visual field defect	219.67	31.52	69	9383	8976	79725960
Drug ineffective	210.18	31.52	419	9033	1080494	78654442
Drug resistance	190.09	31.52	95	9357	42118	79692818
Multiple-drug resistance	188.37	31.52	61	9391	8747	79726189
Somnolence	178.69	31.52	178	9274	238803	79496133
Infantile spasms	166.68	31.52	29	9423	259	79734677
Epilepsy	166.60	31.52	86	9366	40774	79694162
Irritability	151.79	31.52	81	9371	41063	79693873
Brain operation	148.38	31.52	30	9422	635	79734301
Partial seizures	139.84	31.52	49	9403	8929	79726007
Respiratory distress	103.84	31.52	72	9380	58267	79676669
Optic atrophy	102.04	31.52	27	9425	1906	79733030
Aggression	98.05	31.52	66	9386	50892	79684044
Generalised tonic-clonic seizure	96.99	31.52	62	9390	43848	79691088
Sudden unexplained death in epilepsy	96.30	31.52	21	9431	647	79734289
Tonic convulsion	93.72	31.52	26	9426	2194	79732742
Bronchiolitis	93.59	31.52	30	9422	4158	79730778
Anticonvulsant drug level above therapeutic	89.61	31.52	22	9430	1149	79733787
Excessive eye blinking	81.46	31.52	22	9430	1679	79733257
Seizure cluster	77.13	31.52	16	9436	386	79734550
Pneumonia	76.48	31.52	210	9242	660036	79074900
Pneumonia aspiration	75.61	31.52	63	9389	66904	79668032
Focal dyscognitive seizures	73.75	31.52	24	9428	3488	79731448
Gaze palsy	69.10	31.52	22	9430	2983	79731953
Abnormal behaviour	67.25	31.52	46	9406	36375	79698561
Retinal disorder	64.11	31.52	19	9433	2028	79732908
Respiratory disorder	63.03	31.52	48	9404	44808	79690128
Change in seizure presentation	61.98	31.52	14	9438	508	79734428
Myoclonic epilepsy	60.46	31.52	18	9434	1952	79732984
Respiratory syncytial virus infection	60.21	31.52	27	9425	9375	79725561
Respiratory failure	59.35	31.52	89	9363	180822	79554114
Rhinovirus infection	57.92	31.52	25	9427	7928	79727008
Hypotonia	55.04	31.52	28	9424	12842	79722094
Electroencephalogram abnormal	52.84	31.52	21	9431	5413	79729523
Posture abnormal	52.25	31.52	19	9433	3847	79731089
Petit mal epilepsy	51.77	31.52	21	9431	5706	79729230
Viral infection	49.64	31.52	41	9411	42975	79691961
Postictal paralysis	49.53	31.52	11	9441	369	79734567
Crying	49.53	31.52	32	9420	23011	79711925
Febrile convulsion	48.91	31.52	13	9439	933	79734003
Ophthalmological examination abnormal	46.98	31.52	8	9444	62	79734874
Nausea	46.67	31.52	28	9424	957168	78777768
Pain	46.52	31.52	13	9439	703789	79031147
Eye movement disorder	44.99	31.52	21	9431	7990	79726946
Anticonvulsant drug level decreased	43.81	31.52	14	9438	1920	79733016
Coma blister	42.81	31.52	9	9443	232	79734704
Temporal lobe epilepsy	42.48	31.52	10	9442	436	79734500
Acute kidney injury	41.76	31.52	6	9446	519398	79215538
Strabismus	40.17	31.52	14	9438	2507	79732429
Infantile spitting up	39.68	31.52	6	9446	19	79734917
Cerebral disorder	38.99	31.52	17	9435	5521	79729415
Visual impairment	38.61	31.52	51	9401	92080	79642856
Intramyelinic oedema	37.27	31.52	5	9447	4	79734932
Encephalopathy	35.76	31.52	42	9410	67355	79667581
Enterovirus infection	35.65	31.52	12	9440	1935	79733001
Arthralgia	35.17	31.52	12	9440	571791	79163145
Dyskinesia	34.50	31.52	34	9418	44739	79690197
Dysmetria	33.80	31.52	10	9442	1061	79733875
Gingival atrophy	32.42	31.52	6	9446	78	79734858
Lissencephaly	32.16	31.52	4	9448	0	79734936
Intellectual disability	31.74	31.52	10	9442	1310	79733626

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N03AG04	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Fatty acid derivatives
FDA EPC	N0000175753	Anti-epileptic Agent
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:63674	4-aminobutyrate transaminase inhibitors
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018682	GABA Agents
MeSH PA	D018377	Neurotransmitter Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
West syndrome	indication	28055006
Epilepsy characterized by intractable complex partial seizures	indication	442481002
Suicidal thoughts	contraindication	6471006
Weight gain finding	contraindication	8943002
Visual field defect	contraindication	12184005
Reduced visual acuity	contraindication	13164000
Mood swings	contraindication	18963009
Kidney disease	contraindication	90708001	DOID:557
Edema	contraindication	267038008
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Peripheral nerve disease	contraindication	302226006
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.94	acidic
pKa2	10.16	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
4-aminobutyrate aminotransferase, mitochondrial	Enzyme	P80404	GABT_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Gamma-amino-N-butyrate transaminase	Enzyme		GABT_RAT		IC50	4.38	CHEMBL
4-aminobutyrate aminotransferase, mitochondrial	Enzyme		GABT_MOUSE		IC50	4.40	CHEMBL

External reference:

ID	Source
4025280	VUID
N0000171807	NUI
D00535	KEGG_DRUG
4025280	VANDF
C0048044	UMLSCUI
CHEBI:63638	CHEBI
CHEMBL89598	ChEMBL_ID
5665	PUBCHEM_CID
DB01080	DRUGBANK_ID
D020888	MESH_DESCRIPTOR_UI
5581	INN_ID
4821	IUPHAR_LIGAND_ID
GR120KRT6K	UNII
14851	RXNORM
15507	MMSL
36115	MMSL
52922	MMSL
d04669	MMSL
003774	NDDF
310283001	SNOMEDCT_US
322976008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0652	TABLET	500 mg	ORAL	ANDA	33 sections
Vigabatrin for oral solution USP, 500 mg	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0702	FOR SOLUTION	50 mg	ORAL	ANDA	33 sections
Vigabatrin for oral solution USP, 500 mg	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0702	FOR SOLUTION	50 mg	ORAL	ANDA	33 sections
VIGADRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0556	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	35 sections
VIGADRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0245-6001	TABLET	500 mg	ORAL	ANDA	36 sections
VIGABATRIN	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0201	TABLET	500 mg	ORAL	ANDA	31 sections
VIGABATRIN	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0470	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	32 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3851	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3851	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3955	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	30 sections
vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3955	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	30 sections
vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3955	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	30 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-521	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	33 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-521	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	33 sections
vigabatrin for oral solution	HUMAN PRESCRIPTION DRUG LABEL	1	31722-009	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	36 sections
Vigabatrin	Human Prescription Drug Label	1	42799-950	TABLET	500 mg	ORAL	ANDA	30 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	43598-651	TABLET, FILM COATED	500 mg	ORAL	ANDA	32 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	43598-697	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	30 sections
VIGABATRIN	HUMAN PRESCRIPTION DRUG LABEL	1	49884-358	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	32 sections
Vigabatrin	Human Prescription Drug Label	1	59651-366	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	32 sections
Vigabatrin	Human Prescription Drug Label	1	59651-367	TABLET	500 mg	ORAL	ANDA	31 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1424	TABLET	500 mg	ORAL	ANDA	28 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	64850-940	FOR SOLUTION	50 mg	ORAL	ANDA	33 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-111	TABLET, FILM COATED	500 mg	ORAL	NDA	31 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-111	TABLET, FILM COATED	500 mg	ORAL	NDA	31 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-211	POWDER, FOR SOLUTION	50 mg	ORAL	NDA	32 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-211	POWDER, FOR SOLUTION	50 mg	ORAL	NDA	32 sections
VIGABATRIN	Human Prescription Drug Label	1	67877-674	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	31 sections
VIGABATRIN	Human Prescription Drug Label	1	67877-674	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	31 sections
VIGABATRIN	Human Prescription Drug Label	1	67877-674	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	31 sections